$44.77 0.8%
RNA Stock Price vs. AI Score (Last 150 days)
Data gathered: July 18

AI Score

Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Avidity Biosciences

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics.

Avidity Biosciences
Price $44.77
Target Price Sign up
Volume 1,310,000
Market Cap $4.91B
Year Range $5.48 - $46.68
Dividend Yield 0%
Revenue per Employee $58,441
Industry Biotechnology

In the news

Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '243.5M14M-10M-69M-77M-0.790
Q4 '232.2M16M-14M-60M-66M-0.790
Q3 '232.8M14M-11M-52M-58M-0.710
Q2 '232.3M12M-10M-47M-52M-0.660
Q1 '232.2M12M-9.8M-52M-58M-0.740

Insider Transactions View All

Boyce Sarah filed to sell 205,043 shares at $39.9.
July 11 '24
LEVIN ARTHUR A filed to sell 14,830 shares at $37.6.
June 21 '24
McCarthy Teresa filed to sell 32,171 shares at $39.1.
June 20 '24
Flanagan W. Michael filed to sell 50,765 shares at $39.1.
June 20 '24
Boyce Sarah filed to sell 142,543 shares at $39.1.
June 20 '24

What is the Market Cap of Avidity Biosciences?

The Market Cap of Avidity Biosciences is $4.91B.

How Many People Work at Avidity Biosciences?

As of our latest update, Avidity Biosciences employed approximately 186 people worldwide. However, it's important to note that Avidity Biosciences' workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is Avidity Biosciences' revenue per employee?

$58,441. To calculate Avidity Biosciences' revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of Avidity Biosciences?

Currently, the price of one share of Avidity Biosciences stock is $44.77.

How can I analyze the RNA stock price chart for investment decisions?

The RNA stock price chart above provides a comprehensive visual representation of Avidity Biosciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Avidity Biosciences shares. Our platform offers an up-to-date RNA stock price chart, along with technical data analysis and alternative data insights.

Does RNA offer dividends to its shareholders?

As of our latest update, Avidity Biosciences (RNA) does not offer dividends to its shareholders. Investors interested in Avidity Biosciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Avidity Biosciences?

Some of the similar stocks of Avidity Biosciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.